Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | FPR2 | P25090 | 2/20 | 0.50 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097817 | 0.89 | EPHX2 (0.56) | MMP13MMP2FPR2PROKR1EPHX2 | |
| SCHEMBL6401146 | 0.86 | GPR119 (0.59) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6397355 | 0.84 | MMP13 (0.50) | MMP13MMP2FPR2PROKR1MMP12 | |
| Hydrochloric Acid SCHEMBL6395011 | 0.81 | FPR2 (0.54) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL1807395 | 0.79 | MMP2 (0.49) | MMP2EPHX2LIPE | |
| SCHEMBL6692336 | 0.79 | MMP13 (0.51) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6094119 | 0.79 | MMP13 (0.57) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6097984 | 0.79 | MMP13 (0.55) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6397071 | 0.78 | FPR2 (0.52) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL2089684 | 0.77 | EPHX2 (0.60) | MMP13MMP2FPR2PROKR1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004091549-A2 | PROCESS FOR MAKING ALPHA-SUBSTITUTED HYDROXAMIC ACIDS | PHARMACIA CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | HAAO, RIMKLA, ASPH | MMP13 104/4885MMP2 1180/4885FPR2 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.